Kovitz Investment Group Partners LLC Sells 115,596 Shares of Zoetis Inc. $ZTS

Kovitz Investment Group Partners LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 85.0% in the 4th quarter, HoldingsChannel reports. The firm owned 20,448 shares of the company’s stock after selling 115,596 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Zoetis were worth $2,573,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the 4th quarter worth $25,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis in the 4th quarter valued at $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis in the 3rd quarter valued at $31,000. Finally, Holos Integrated Wealth LLC bought a new stake in Zoetis during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on ZTS shares. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. UBS Group decreased their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Finally, BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $133.92.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, The Gross Law Firm, Kessler Topaz, Bragar Eagel & Squire, and others, announced or reiterated securities class actions against Zoetis, with claims tied to alleged misstatements and omissions about product adoption during the January 14, 2025 to May 6, 2026 period. Article Title
• Negative Sentiment: The lawsuits highlighted a July 27, 2026 lead-plaintiff deadline and suggested investors who bought ZTS during the class period may have suffered losses, increasing legal overhang and uncertainty for the stock. Article Title
• Neutral Sentiment: Zacks noted ZTS recently outperformed the broader market, but that commentary was largely backward-looking and did not change the heavier focus on litigation headlines. Article Title

Insider Activity

In other news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by insiders.

Zoetis Stock Performance

Shares of ZTS opened at $78.69 on Friday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $161.77. The company has a market cap of $32.99 billion, a PE ratio of 13.05, a price-to-earnings-growth ratio of 1.23 and a beta of 0.75. The stock has a 50-day moving average price of $93.01 and a 200-day moving average price of $112.54.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.